胃癌患者血清miR-892b、GROβ水平与临床病理特征、预后的关系  

Relationship between serum miR-892b and GROβlevels and clinicopathological features and prognosis in patients with gastric cancer

作　　者：文思敏 吕婷 雷蕾 王玲玲 史良玉 WEN Simin;LYU Ting;LEI Lei;WANG Lingling;SHI Liangyu(Department of Gastroenterology,Shaanxi Provincial Nuclear Industry 215 Hospital,Xianyang,Shaanxi 712000,China)

机构地区：[1]陕西省核工业二一五医院消化内科,陕西咸阳712000

出　　处：《国际检验医学杂志》2024年第20期2506-2510,共5页International Journal of Laboratory Medicine

基　　金：咸阳市科学技术局项目(L2022ZDYFSF027)。

摘　　要：目的探讨胃癌患者血清微小RNA-892b(miR-892b)、生长相关癌基因产物β(GROβ)水平及其临床意义。方法选取2019年2月至2022年2月该院收治的124例胃癌患者为胃癌组,并同期选取100例胃镜检查正常的体检志愿者为对照组。检测两组血清miR-892b、GROβ水平,分析血清miR-892b、GROβ水平与胃癌患者临床病理特征的关系,采用多因素Cox回归分析探讨胃癌患者预后的影响因素。结果胃癌组血清miR-892b水平低于对照组、血清GROβ水平高于对照组(P<0.05)。不同分化程度、肿瘤最大径、淋巴结转移、TNM分期的胃癌患者血清miR-892b、GROβ水平比较,差异有统计学意义(P<0.05)。对124例胃癌患者出院后连续随访1年,91例患者存活,总生存率为73.39%。胃癌患者1年总生存率与其分化程度、肿瘤最大径、淋巴结转移、TNM分期有关(P<0.05)。血清miR-892b高表达、GROβ低表达胃癌患者1年总生存率分别高于血清miR-892b低表达、GROβ高表达患者(P<0.05)。多因素Cox回归分析显示,低分化程度(HR=1.839,95%CI 1.048~3.227),淋巴结转移(HR=1.791,95%CI 1.076~2.982),TNM分期Ⅲ~Ⅳ期(HR=1.660,95%CI 1.015~2.715),血清miR-892b低表达(HR=3.040,95%CI 1.592~5.805),血清GROβ高表达(HR=2.277,95%CI 1.503~3.451)是影响胃癌患者预后的危险因素(P<0.05)。结论胃癌患者血清miR-892b水平降低,GROβ水平升高,与胃癌的发生及发展密切相关,二者表达均与患者临床病理特征和预后有关,可作为辅助评估胃癌患者预后的生物学指标。Objective To investigate the serum levels of microRNA-892b(miR-892b)and growth-associated oncogene productβ(GROβ)in patients with gastric cancer and their clinical significance.Methods A total of 124 patients with gastric cancer admitted to the hospital from February 2019 to February 2022 were selected as the gastric cancer group,and 100 volunteers with normal gastroscopy were selected as the control group during the same period.Serum levels of miR-892b and GROβwere detected in the two groups,and the relationship between serum levels of miR-892b and GROβand clinicopathological characteristics of patients with gastric cancer was analyzed.Multivariate Cox regression analysis was used to explore the influencing factors of prognosis of patients with gastric cancer.Results The serum level of miR-892b in gastric cancer group was lower than that in control group,and the serum level of GROβwas higher than that in control group(P<0.05).There were statistically significant differences in serum miR-892b and GROβlevels in gastric cancer patients with different degrees of differentiation,maximum tumor diameter lymph node metastasisand TNM stage(P<0.05).A total of 124 patients with gastric cancer were followed up for one year after discharge,91 patients survived,and the overall survival rate was 73.39%.The one year overall survival rate of gastric cancer patients was related to the degree of differentiation,maximum tumor diameter,lymph node metastasis and TNM stage(P<0.05).The overall survival rate of gastric cancer patients with high expression of serum miR-892b and low expression of GROβwas higher than that of patients with low expression of serum miR-892b and high expression of GROβ(P<0.05).Multivariate Cox regression analysis showed poor differentiation(HR=1.839,95%CI 1.048—3.227),lymph node metastasis(HR=1.791,95%CI 1.076—2.982),TNM stageⅢ—Ⅳ(HR=1.660,95%CI 1.015—2.715),low expression of serum miR-892b(HR=3.040,95%CI 1.592—5.805),high expression of serum GROβ(HR=2.277,95%CI 1.503—3.451)were risk fa

关 键 词：胃癌 微小RNA-892b 生长相关癌基因产物β 预后 

分 类 号：R735.2[医药卫生—肿瘤]